Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency-Reference-Cited by-同舟云学术

Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency

Published:2014-08-14 Issue:1-2 Volume:4 Page:41-55
ISSN:2195-5840
Container-title:Biologics in Therapy
language:en
Short-container-title:Biol Ther

Author:

Sidhu Jagdev,Rojavin Mikhail,Pfister Marc,Edelman Jonathan

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1007/s13554-014-0018-0

Reference48 articles.

1. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med. 2000;343(18):1313–24.

2. Chapel H, Geha R, Rosen F. Primary immunodeficiency diseases: an update. Clin Exp Immunol. 2003;132(1):9–15.

3. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.

4. Lougaris V, Ferrari S, Plebani A. Ig beta deficiency in humans. Curr Opin Allergy Clin Immunol. 2008;8(6):515–9.

5. Notarangelo LD, Fischer A, Geha RS, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161–78.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens;Journal of Clinical Immunology;2023-05-09

2. Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience With Enhanced Infusion Regimens;2023-03-24

3. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies;International Immunopharmacology;2022-12

4. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases;International Immunopharmacology;2022-03

5. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients;Frontiers in Immunology;2022-01-17